CN Patent

CN117263849A — 一种雷芬那辛三水合物晶型及其制备方法

Assigned to Jewim Pharmaceutical Shandong Co ltd · Expires 2023-12-22 · 2y expired

What this patent protects

本发明涉及雷芬那辛三水合物晶型A及其制备方法，此晶型具有良好的化学稳定性、晶型纯度及较好的水溶性，满足了在大生产设备上操作的可行性；同时此晶型也大大提高了制剂产品的稳定性。能够更好地适用于制备药物制剂和规模化生产，具有广阔的应用前景。

USPTO Abstract

本发明涉及雷芬那辛三水合物晶型A及其制备方法，此晶型具有良好的化学稳定性、晶型纯度及较好的水溶性，满足了在大生产设备上操作的可行性；同时此晶型也大大提高了制剂产品的稳定性。能够更好地适用于制备药物制剂和规模化生产，具有广阔的应用前景。

Drugs covered by this patent

Patent Metadata

Patent number
CN117263849A
Jurisdiction
CN
Classification
—
Expires
2023-12-22
Drug substance claim
No
Drug product claim
No
Assignee
Jewim Pharmaceutical Shandong Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.